A carregar...
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
INTRODUCTION: The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival. However, the drug has little effect on the underlying bone marrow fibrosis o...
Na minha lista:
| Publicado no: | Expert Opin Orphan Drugs |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577425/ https://ncbi.nlm.nih.gov/pubmed/33094033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2019.1664900 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|